Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a multi-center study in France to evaluate the impact of ESTROTEP PET/CT results on
the therapeutic management of patients with metastatic breast cancer (MBC).
Each patient will be screened to determine whether the patient meets all the inclusion
criteria and none of the exclusion criteria.
After inclusion, a standardized pre ESTROTEP PET/CT questionnaire will be completed by the
investigators to evaluate the initial management plan. Patient will perform the ESTROTEP
PET/CT examination at visit 2. A standardized post ESTROTEP PET/CT questionnaire will then be
completed by the investigators.
Patients will be followed for 12 months to evaluate their clinical status and standard of
care investigations.